Vericel (NASDAQ:VCEL) Releases Earnings Results

Vericel (NASDAQ:VCEL) issued its quarterly earnings data on Thursday. The biotechnology company reported $0.45 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.45, FiscalAI reports. The business had revenue of $92.92 million during the quarter, compared to analysts’ expectations of $92.66 million. Vericel had a return on equity of 4.30% and a net margin of 5.06%.The company’s revenue for the quarter was up 23.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.38 EPS.

Here are the key takeaways from Vericel’s conference call:

• The company reported record Q4 revenue of $92.9M (up 23% YoY) and MACI Q4 revenue of $84.1M, delivered record net income and industry-leading margins (Q4 gross margin ~79% and adjusted EBITDA margin 40%), and ended 2025 with ~$200M cash and no debt.
• Management guided 2026 revenue to approximately $316M–$326M (MACI: $280M–$286M; Burn Care: $36M–$40M), expects Q1 company growth >20% and MACI Q1 of ~$54M–$55M, leaving room for upside if momentum continues.
• Key commercial drivers include a ~30% expansion of the MACI sales force and ~1,000 MACI Arthro‑trained surgeons, with Arthro-trained and implanting surgeons showing higher biopsy, implant and conversion rates that management expects to further penetrate existing practices.
• Guidance factors include higher operating costs (OpEx ~$220M) and near-term margin pressure from Burlington manufacturing start‑up and the Phase 3 MACI Ankle trial, and management did not include potential BARDA NexoBrid award revenue in its 2026 guidance due to timing uncertainty.

Vericel Stock Up 1.6%

VCEL stock opened at $37.68 on Friday. Vericel has a 52 week low of $29.24 and a 52 week high of $55.41. The firm has a 50-day simple moving average of $37.11 and a 200-day simple moving average of $36.13. The stock has a market capitalization of $1.91 billion, a P/E ratio of 157.01 and a beta of 1.24.

Analyst Ratings Changes

A number of research analysts have issued reports on VCEL shares. Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a report on Sunday, January 25th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Vericel in a report on Monday, December 29th. Zacks Research downgraded shares of Vericel from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Finally, Truist Financial dropped their price target on shares of Vericel from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Institutional Investors Weigh In On Vericel

Several large investors have recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new position in shares of Vericel during the fourth quarter valued at approximately $27,000. Quarry LP acquired a new stake in shares of Vericel in the fourth quarter worth approximately $31,000. Truvestments Capital LLC increased its position in shares of Vericel by 175.4% during the fourth quarter. Truvestments Capital LLC now owns 1,534 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 977 shares in the last quarter. Empowered Funds LLC acquired a new position in Vericel in the 4th quarter valued at $58,000. Finally, Osaic Holdings Inc. raised its stake in Vericel by 13.7% in the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 353 shares during the last quarter.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.